Arrowhead Research (ARWR) PT Raised to $50 at Piper Jaffray

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Arrowhead Research (ARWR) PT Raised to $50 at Piper Jaffray

Arrowhead Pharmaceuticals Corp (ARWR) Reports First Patient Dosing in SEQUOIA Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

August 8, 2019 7:40 AM EDT

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in SEQUOIA (AROAAT2001), a potentially pivotal Phase 2/3 clinical study of ARO-AAT, the companys second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD).

Bruce Given, M.D., chief operating officer and head of R&D at Arrowhead, said: ARO-AAT... More